TVM Capital

We provide more than just capital, working with founders from scratch to success. By working with the leading companies in this field we will advance and redefine the standard of patient care. These products were revolutionary yesterday, nascent today, and will be world changing tomorrow. Compounds, clinics and care delivery, digital therapeutics and platforms. Deep sector expertise in broad technology, med-tech, pharmaceuticals and biologics.

We invest in opportunities such as medical devices, drug delivery systems, and diagnostics, as well as longer range investments in biopharma products and platforms. Central to our strategy is the belief that significantly more value can be created from the formation and initial management of leading edge life science companies than from traditional venture capital investing in pre-existing companies, whether at early or later stages.

As we access new assets, we set up new subsidiaries to provide the focus required to advance these into and through the clinic. Making a good idea in medicine into a product is a difficult and expensive process. We have assembled highly experienced team of pharmaceutical experts bolstered by a network of advisors and service providers to deploy on late pre-clinical and early clinical assets to accelerate their development into products. Capitalize on access to innovative preclinical and early-stage clinical products and technology. Leverage an integrated ecosystem of development organizations and internal expertise to accelerate product development timelines. Monetize investments through strategic and well-timed out-licensing, sale or IPO of each product to provide liquidity to investors and the best path to bringing products to patients. Acquire pipeline of differentiated products to meet underserved medical needs. Provide excellent returns to investors by delivering superior products to patients.

Investments in healthcare ventures with lasting impact for patients and society. We invest in healthcare innovation, from start-up to scale-up. We treasure daring entrepeneurs and have a keen eye for paradigm shifting ideas. We help to start, build and accelarate ventures with tranched investments, balancing risk and return. We build sustainable value by supporting the development of novel therapies in areas of high unmet medical need.

We invest in biotechnology companies passionate about bringing novel therapies to patients. With a background in the pharmaceutical, biotechnology and CRO industries, our investment team brings a wealth of practical experience to portfolio, companies from spinoff to public market listing. Our investment approach is primarily focused around therapeutics. We look for novel drugs and modalities in a wide variety of disease areas, and invest across the spectrum of drug development. We are equally comfortable in company formation, as we are in participating in syndicates with co-investors.

We are actively involved with our companies as board members, preferably as lead investor. Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors. We identify innovative solutions to chronic health conditions where the burden to both patients and reimbursement systems is high. We support projects for promising solutions in chronic health conditions, with a focus on alleviating patient and societal burdens. Drawing on our team’s scientific and medical know-how, as well as a network of experts, we seek to identify the most promising investment opportunities.